CapsicoHealth reposted this
CapsicoHealth is very excited to announce our next version of Gen-AI based Patient Pathway analyses and prediction tools for precision-medicine in Oncology, and in specific Radioligand therapies for Cancer Care. We are also extremely pleased to announce the acceptance of our Gen-AI driven pathway analyses method for precision-care for a podium presentation at the prestigious INFORMS conference, 2024, Seattle.
Every year over 250,000 men are diagnosed with Prostate cancer, contributing to more than 30,000 annual deaths, a 5-year survival rate of only 30%. Prostate-specific membrane antigen (PSMA) targeted PET tracers, along with Radioligand Therapy (RLT) represents a promising new approach to Prostate Cancer treatment in advanced precision-medicine, with 50% reduction in PSA and survival improvement of over 30%. CapsicoHealth is very excited to announce our next version of Gen-AI based Patient Pathway analyses and prediction tools for precision-medicine in Oncology, and in specific Radioligand therapies for Cancer Care. We are also extremely pleased to announce the acceptance of our Gen-AI driven pathway analyses method for precision-care for a podium presentation at the prestigious INFORMS conference, 2024, Seattle. CapsicoHealth’s Context-aware LLM tools predict patient pathways including identifying at-risk patients for early treatment, potentially predicting disease progression and driving critical insights for care and supply chain planning.